The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Highlights from ASH 2019 for transplant eligible patients with NDMM

Dec 12, 2019

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Sagar Lonial, Winship Cancer Institute at Emory University, Atlanta, US, discusses the highlights from ASH 2019 for transplant eligible patients with newly diagnosed multiple myeloma.

Sagar Lonial talks about key highlights and clinical trial data for transplant eligible patients with NNMM. He discusses the results from the CASSIOPEIA trial and GRIFFIN trial. He concludes by noting that new drugs and new targets give patients more treatment options

Highlights from ASH 2019 for transplant eligible patients with NDMM